BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu Y, Wang S, Zhao X, Feng Y, Bormans G, Swinnen J, Oyen R, Huang G, Ni Y, Li Y. Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation. Diagnostics (Basel) 2020;10:E78. [PMID: 32024029 DOI: 10.3390/diagnostics10020078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Meng F, Zou B, Yang R, Duan Q, Qian T. The diagnostic efficiency of the perfusion-related parameters in assessing the vascular disrupting agent (CA4P) response in a rabbit VX2 liver tumor model. Acta Radiol 2021;:2841851211032450. [PMID: 34279135 DOI: 10.1177/02841851211032450] [Reference Citation Analysis]
2 Liu L, O'Kelly D, Schuetze R, Carlson G, Zhou H, Trawick ML, Pinney KG, Mason RP. Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors. Molecules 2021;26:2551. [PMID: 33925707 DOI: 10.3390/molecules26092551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Smolarczyk R, Czapla J, Jarosz-Biej M, Czerwinski K, Cichoń T. Vascular disrupting agents in cancer therapy. Eur J Pharmacol 2021;891:173692. [PMID: 33130277 DOI: 10.1016/j.ejphar.2020.173692] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Atanasov G, Rusew RI, Gelev VM, Chanev CD, Nikolova R, Shivachev BL, Petrov OI, Apostolova MD. New Heterocyclic Combretastatin A-4 Analogs: Synthesis and Biological Activity of Styryl-2(3H)-benzothiazolones. Pharmaceuticals (Basel) 2021;14:1331. [PMID: 34959731 DOI: 10.3390/ph14121331] [Reference Citation Analysis]